Neuralstem (NASDAQ: CUR) and Opko Health (NASDAQ:OPK) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Risk and Volatility

Neuralstem has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Institutional & Insider Ownership

5.8% of Neuralstem shares are held by institutional investors. Comparatively, 22.3% of Opko Health shares are held by institutional investors. 15.4% of Neuralstem shares are held by insiders. Comparatively, 40.2% of Opko Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Neuralstem and Opko Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Neuralstem -5,351.20% -5.58% -3.64%
Opko Health -9.45% -5.17% -3.94%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Neuralstem and Opko Health, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neuralstem 0 0 0 0 N/A
Opko Health 0 2 6 0 2.75

Neuralstem currently has a consensus price target of $3.18, suggesting a potential upside of 200.00%. Opko Health has a consensus price target of $14.81, suggesting a potential upside of 209.88%. Given Opko Health’s higher possible upside, analysts plainly believe Opko Health is more favorable than Neuralstem.

Valuation and Earnings

This table compares Neuralstem and Opko Health’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Neuralstem $20,000.00 802.95 -$21.07 million ($1.66) -0.64
Opko Health $1.22 billion 2.19 -$25.08 million ($0.19) -25.16

Neuralstem has higher revenue, but lower earnings than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Neuralstem, indicating that it is currently the more affordable of the two stocks.


Opko Health beats Neuralstem on 9 of the 12 factors compared between the two stocks.

Neuralstem Company Profile

Neuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company’s technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company’s NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.

Opko Health Company Profile

OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.